Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Evaluation of dosing strategy for pembrolizumab for oncology indications

Fig. 3

Consistency of observed concentrations in patients with predictions based on population PK model: Pembrolizumab concentration-time profiles during the first dose (left panels) and at steady state (right panels) of repeated dosing at 2 mg/kg Q3W (top panels) and 200 mg Q3W (bottom panels). Solid markers represent observed pembrolizumab serum concentrations. Solid line represents median predicted concentration time profile, based on the population PK model. Shaded areas represent 90% prediction interval for the prediction

Back to article page